19.02.2020 HumanOptics AG  DE000A1MMCR6

DGAP-News: HumanOptics AG: CE-marking for innovative trifocal lens TRIVA(R)


 

DGAP-News: HumanOptics AG / Key word(s): Miscellaneous
HumanOptics AG: CE-marking for innovative trifocal lens TRIVA(R)

19.02.2020 / 16:39
The issuer is solely responsible for the content of this announcement.


HumanOptics: CE-marking for innovative trifocal lens TRIVA(R)

Erlangen, 18 February 2020 - HumanOptics AG has received CE marking and thus approval on the European market for its new trifocal lens TRIVA-aA. With this innovative intraocular lens (IOL), the specialist for high-quality ophthalmic surgery implants is expanding its range in the rapidly growing premium lens segment.

TRIVA-aA is the first multifocal lens from HumanOptics with three focal points. Its optimized design enables patients to enjoy good vision not only at long and near distances, but also at medium distances. It is therefore particularly suitable for screen work or the use of tablets and smartphones and is tailored to the requirements of a modern, digital living environment in today's society.

The novel lens is used in cataract surgery, which is becoming increasingly important due to demographic developments. Cataract surgery is getting an increasingly refractive character, which means that in addition to cataracts, ametropia is also corrected.

The novel trifocal lenses are produced with high-precision sub-nano resolution (SNR) technology in Germany. This technology, which can only be realized by using appropriate ultra-precision lathes and makes subsequent polishing superfluous, makes HumanOptics the world leader.

Company profile:

HumanOptics AG (www.humanoptics.com) specializes in the development, production and sale of high-quality implants and accessories for ophthalmic surgery and stands for the highest quality and innovative strength in this segment. The most important products are intraocular lenses (IOL) for the treatment of cataracts and various forms of ametropia as well as artificial irises. In addition, the company offers the operating ophthalmologists accessories and complementary products as well as comprehensive consulting services. The shares of HumanOptics AG are listed on the Basic Board of the Frankfurt Stock Exchange.

Contact us:

HumanOptics AG
Investor Relations
Spardorfer Str. 150
91054 Erlangen
Germany
Phone: +49 (0) 9131 50665-0
E-Mail: [email protected]



19.02.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: HumanOptics AG
Spardorfer Str. 150
91054 Erlangen
Germany
Phone: +49 (0)9131 - 50665-60
Fax: +49 (0)9131 - 50665-93
E-mail: [email protected]
Internet: www.humanoptics.de
ISIN: DE000A1MMCR6, DE000A255FK8
WKN: A1MMCR
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Stuttgart
EQS News ID: 979341

 
End of News DGAP News Service

979341  19.02.2020 

fncls.ssp?fn=show_t_gif&application_id=979341&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 10,51 11,56 11,04 10,68 9,36 10,20 0,00
EBITDA1,2 0,82 0,54 -1,28 -1,27 -1,90 0,80 0,00
EBITDA-Marge3 7,80 4,67 -11,59 -11,89 -20,30 7,84 0,00
EBIT1,4 0,33 0,13 -1,71 -1,76 -2,42 0,34 0,00
EBIT-Marge5 3,14 1,12 -15,49 -16,48 -25,86 3,33 0,00
Jahresüberschuss1 0,16 0,03 -1,78 -1,89 -2,57 -0,25 0,00
Netto-Marge6 1,52 0,26 -16,12 -17,70 -27,46 -2,45 0,00
Cashflow1,7 0,99 0,53 -1,30 -1,84 -1,53 0,30 0,00
Ergebnis je Aktie8 0,05 0,01 -0,58 -0,60 -0,74 -0,07 0,29
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ebner Stolz

INVESTOR-INFORMATIONEN
©boersengefluester.de
HumanOptics
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A1MMCR 9,000 Halten 31,39
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
21,43 34,23 0,63 -57,33
KBV KCV KUV EV/EBITDA
12,06 - 3,35 -18,76
Dividende '19 in € Dividende '20e in € Div.-Rendite '20e
in %
Hauptversammlung
0,00 0,00 0,00 18.12.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 03.12.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-0,73% -6,46% 8,43% 17,65%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu HumanOptics AG  ISIN: DE000A1MMCR6 können Sie bei DGAP abrufen

Medtech , A1MMCR , H9O1 , FWB:H9O1